Benchmark Maintains Buy on Abbott Laboratories, Lowers Price Target to $120

Benzinga Newsdesk www.benzinga.com Negative 54.7%

Neg 54.7% Neu 0% Pos 0%

Benchmark analyst Bruce D. Jackson maintains Abbott Laboratories (NYSE:ABT) with a Buy and lowers the price target from $145 to $120.